New Data on the Use of Investigational Agent Belatacept in Kidney Transplant Recipients to Be Presented at 2010 American Transplant Congress

Eight Presentations Featured, Including Two-Year Phase 3 Data PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY) announced today that belatacept, an investigational selective T cell co-stimulation blocker being studied for use in solid organ transplantation, will be the subject of eight clinical presentations related to kidney transplantation at the American Transplant Congress, being held May 1 – 5 in San Diego. Belatacept, which received a positive U.S. Food and Drug Administration (FDA) advisory committee vote on March 1 of this year, is currently under FDA review for the prophylaxis of organ rejection in adult kidney transplant recipients. In total, 17 abstracts from company-sponsored studies will be presented during the congress. “Our clinical development program for belatacept in kidney transplant recipients demonstrates our ongoing commitment to developing targeted biologic therapies for patients with serious disease,” said Brian Daniels, M.D. , senior vice president, Global Development and Medical Affairs, Bristol-Myers Squibb. “This year’s congress marks the first presentation of two-year Phase 3 data for belatacept, adding to our ongoing research efforts to better understand how this investigational compound may help kidney transplant recipients." The eight belatacept clinical presentations related to kidney transplantation are as follows: Session Information Presentation Title Lead Author May 2, 2010 4:00 p.m. Ballroom 20D Oral Presentation Belatacept vs Cyclosporine in Kidney Transplant Recipients: Two-Year Outcomes from the BENEFIT Study C. Larsen Emory University Atlanta, GA May 2, 2010 4:12 p.m. Ballroom 20D Oral Presentation Belatacept vs Cyclosporine in ECD Kidney Transplants: Two-Year Outcomes from the BENEFIT-EXT Study A. Durrbach Bicêtre Hospital, Kremlin Bicêtre, France May 2, 2010 4:24 p.m. Ballroom 20D Oral Presentation Safety Profile of Belatacept in Kidney Transplant Recipients from a Pooled Analysis of Phase 2 and Phase 3 Studies J. Grinyó University Hospital of Bellvitge Barcelona, Spain May 3, 2010 8:30 a.m. Hall F Oral Presentation Switch from a CNI- to a Belatacept-Based Immunosuppressive Regimen in Kidney Transplant Recipients Is Safe and Results in Better Renal Function: 12 Month Results from a Phase II Study L. Rostaing University Hospital Toulouse, France May 3, 2010 5:30 p.m - 6:30 p.m. Exhibit Hall E Poster Presentation Belatacept Population Pharmacokinetics in Renal Transplant Patients Z. Zhou Bristol-Myers Squibb Princeton, NJ May 3, 2010 5:30 p.m. - 6:30 p.m. Exhibit Hall E Poster Presentation Pharmacokinetics of Mycophenolic Acid (MPA) with Belatacept- or Cyclosporine (CsA)-Based Regimens L. Rostaing University Hospital Toulouse, France May 4, 2010 2:15 p.m. Ballroom 20D Oral Presentation Immunosuppression with Belatacept-Based, CNI- Avoiding and Steroid- Avoiding Regimens vs a Tacrolimus-Based, Steroid- Avoiding Regimen in Kidney Transplant Patients: Results of a 1-Year, Randomized Study R. Ferguson Ohio State University College of Medicine Columbus, OH May 4, 2010 2:27 p.m. Ballroom 20D Oral Presentation Outcomes as a Function of Donor Criteria from a Phase III Study of Belatacept vs Cyclosporine in Kidney Transplantation (BENEFIT-EXT) S. Florman Mount Sinai Medical Center New York, NY About Bristol-Myers Squibb Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com . Bristol-Myers Squibb CompanyMedia:Laura Hortas, [email protected] McNamara, [email protected]:John Elicker, [email protected]

The release as fetched from its publisher. bms.com ↗